OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is a micro-cap player in the medical cannabis space. OWCP stock has continued to outperform the space with its strong strategic balance and exposure to beneficial governance standards in Israel. OWC Pharmaceutical recently added talent to the team by announcing the appointment of Dr. Sharon Rozenblat as Senior Advisor to the Scientific Advisory Board of its wholly-owned Israeli subsidiary, One World Cannabis Ltd.
According to the release, Dr. Rozenblat will be tasked with overseeing the completion of the pre-clinical safety studies on the Company’s treatment for psoriasis, which commenced in November 2016. Dr. Rozenblat will also steer the Company’s efforts to commercialize OWC’s cannabis-based formulations and delivery mechanisms.
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) bills itself as a company that engages in the research and development of Cannabis-based medical products. The company provides medical products for the treatment of various medical conditions and/or diseases, such as multiple myeloma, psoriasis, PTSD, and migraines; and delivery systems. It also provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations.
OWCP through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals, treatments and unique delivery systems for the effective delivery and dosage of medical cannabis.
All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
OWCP’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. The company was formerly known as Dynamic Applications Corp. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Petach Tikva, Israel.
According to company materials, “OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively “OWC” or the “Company”) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.”
Find out when $OWCP stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
The company’s talent pool was already strong before the addition of Dr. Rozenblat. But this will further ringfence legitimacy on the R&D side and appease regulators. Dr. Yehuda Baruch, OWC’s Chief Scientific Officer, commented on the appointment, “Dr. Rozenblat has had a significant impact in the field of dermatology, specifically with regard to botanical formulations. With more than 15 years’ experience in the research and development of herbal extracts and related products, as well as considerable experience in the design and management of clinical trials, she is the perfect complement to our scientific team.”
This announcement comes on the heels of some aggressive goals recently outlined by the company looking ahead in 2017: 1. During the second quarter of 2017 OWCP intends to initiate its U.S marketing program for its Psoriasis Topical Cream. At the same time, we intend to begin investigating the applicability of topical cream for other skin conditions and disorders. 2. OWCP intends to proceed with the advancement of our cannabis-based treatment for multiple myeloma, with the objective of proceeding with additional studies. And 3. OWCP intends to evaluate the launch of one or more studies to determine the applicability of cannabinoid-based pharmaceuticals for other medical conditions and disorders, such as fibromyalgia and migraines.
We’ve witnessed 66% tacked on to share pricing for the company in the past month. The situation may be worth watching. OWCP has a history of dramatic rallies. Furthermore, the stock has seen an influx in interest of late, with recent average trading volume running 5% over the long run average.
At this time, carrying a capital value in the market of $92.9M, OWCP has about $90K in cash on the books, which must be weighed relative to about $186K in total current liabilities. The company is pre-revenue at this point. As more color becomes clear on the name, we will review the situation and update our take. For continuing coverage on shares of $OWCP stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!
